



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

March 24, 2022

Eric Easom  
Chief Executive Officer  
AN2 Therapeutics, Inc.  
1800 El Camino Real, Suite D  
Menlo Park, CA 94027

**Re: AN2 Therapeutics, Inc.  
Registration Statement on Form S-1  
Exhibit Nos. 10.13 & 10.14  
Filed March 4, 2022  
File No. 333-263295**

Dear Mr. Easom:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance